Showing results (1-10 of 192) with videos related to
Sort By:
Pageof 20
Pharmacology & Therapeutics|January 24, 2015
Ror2 as a therapeutic target in cancerZufan Debebe, W Kimryn RathmellCancer Discovery|April 4, 2024
Using the National Cancer Plan to Drive Innovation in Cancer ResearchW Kimryn RathmellTransactions of the American Clinical and Climatological Association|September 13, 2023
LEARNING TO PIVOT: DEVELOPING TALENT AND A CHAMPIONSHIP TEAMW Kimryn RathmellKidney Cancer (Clifton, Va.)|October 16, 2018
Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)Pooja Ghatalia, W Kimryn RathmellExpert Review of Anticancer Therapy|December 22, 2007
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatmentW Kimryn Rathmell, Shufen ChenCurrent Clinical Pharmacology|April 8, 2011
Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug developmentNeal Rasmussen, W Kimryn RathmellCurrent Oncology Reports|April 29, 2010
Renal cell carcinoma: where will the state-of-the-art lead us?A Rose Brannon, W Kimryn RathmellClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomesDavid D Chism, W Kimryn RathmellClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinomaBrian I Rini, W Kimryn RathmellUrology|July 25, 2008
High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature ReviewW Kimryn Rathmell, J Paul MonkPageof 20